For patients with acute myeloid leukemia (AML) relapsed after allogeneic bone marrow
transplantation (BMT), donor leukocyte infusion (DLI) as sole therapy has very limited …

Donor leukocyte infusion (DLI) alone has very limited efficacy for patients with acute
lymphoblastic leukemia (ALL) who have relapsed after allogeneic bone marrow …

Purpose To evaluate the role of donor lymphocyte infusion (DLI) in the treatment of relapsed
acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation …

To determine whether induction of graft-versus-host disease (GVHD) improves the outcome
of acute relapsed leukemia after stem cell transplantation (SCT), we used high-dose …

Thirty-one consecutive patients with acute myelogenous leukemia (AML) in first complete
remission and 8 with AML in second complete remission received T cell–depleted …

A total of 118 consecutive adult patients with acute leukemia (78 AML, 36 ALL, and four
acute mixed lineage leukemia) underwent allogeneic hematopoietic cell transplantation …

Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML)
relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain …

To clarify the role of donor leukocyte infusion (DLI) in the treatment of leukemia relapsing
after allo-BMT, data from 100 patients were collected from 46 facilities in Japan and …

We investigated the frequency and mode of relapses of acute leukemia after allogeneic BMT
in a series of 50 consecutive patients. The median age of patients was 31.5 years with 26 …

A multi‐centre retrospective analysis on 117 patients relapsing after bone marrow
transplantation (BMT) for acute leukaemia was carried out by the Leukaemia Working Party …